Latest Press Releases
The FDA issued 30 warning letters to GLP-1 telehealth companies in March 2026. This independent advertorial reviews Sprout Health's publicly available program disclosures, compounded semaglutide and tirzepatide pricing, provider and pharmacy transparency, refund policies, and what consumers should verify before enrolling in any compounded GLP-1 telehealth program this year.
A transparent, month-to-month telehealth weight loss program offering fixed-rate GLP-1 support, zero hidden fees, no insurance requirements, and cancel-anytime flexibility for 2025 consumers seeking affordable Semaglutide and Tirzepatide access.
Comprehensive Analysis of the Best NAD+ Injectable in 2025 - Real User Results, Expert Insights, Safety Facts, and Pricing Breakdown
A non-medical overview of how Sprout Health NAD⁺ Injections supports energy, cellular function, and wellness in a remote telehealth setting.
UPDATE - Contact information has been updated on this release as of September 9, 2025
A remote-first, doctor-reviewed telehealth program offering access to personalized care plans and GLP-1 evaluations using semaglutide or tirzepatide.